(Journal Article): Association of Postprandial Hyperglycemia with in Vitro LDL Oxidation in Non-Smoking Patients with Type 1 Diabetes – a Cross-Sectional Study
 
de Castro SH, Castro-Faria-Neto HC, Gomes MB (Department of Medicine, Diabetes Unit, State University Hospital of Rio de Janeiro, Brazil., mariliabgomes(at)uol.com.br )
 
IN: Rev Diabetic Stud 2005; 2(3):157-164
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: BACKGROUND: Cardiovascular disease is the main cause of death in patients with type 1 diabetes. Since oxidized low density lipoprotein (LDL) is considered to be a critical factor in the atherosclerotic process, the aim of our study was to assess the influence of different parameters of glycemic control on susceptibility to oxidative stress from low density lipoprotein (LDL) in patients with type 1 diabetes without microvascular or macrovascular complications. METHODS: Forty patients and 33 non-diabetic individuals matched for gender, age and body mass index (BMI) were evaluated. The two groups underwent determination of lipid profile, fasting and postprandial glucose control and measurement of glycated hemoglobin (HbA1c). Spectrophotometric analysis of the LDL oxidation index was performed before and 1, 3, 6 and 24 hours after the addition of copper sulfate to purified LDL fractions. RESULTS: The oxidation coefficient for LDL presented similar basal values in the two groups; however, at 3 h, LDL showed a higher degree of oxidation in patients with type 1 diabetes. Correlations with the metabolic control variables were significant only for postprandial glycemia. Stepwise multiple regression showed that post-prandial glycemia and sex were the significant independent variables. CONCLUSION: LDL from patients with type 1 diabetes showed high susceptibility to oxidative stress and this susceptibility was markedly related to the postprandial glucose levels. The influence of our findings on the development of chronic complications in patients with type 1 diabetes must be addressed in prospective studies.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB 1992. 6:2905-2914.
2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001. 44 (Suppl 2):S14-S21.
3. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, EA, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003. 46:760-765.
4. Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL, Morris AD, Waugh NR, Gatling W, Gale EA, Patterson CC, Qiao Z, Keen H. Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 2003. 34:418-421.
5. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993. 329:977-986.
6. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S; Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003. 348:2294-2303.
7. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kubota M, Kajimoto Y, Kamada T. Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia 1995. 38:585-591.
8. Jarvisalo MJ, Putto-Laurila A, Jartti L, Lehtimäki T, Solakivi T, Rönnemaa T, Raitakari OT. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 2002. 51:493-498.
9. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 2005. 19:178-181.
10. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999. 44:937-942.
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 2000. 321:405-412.
12. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998. 15:188-193.
13. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997. 96:25-28.
14. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996. 271:C1424-C 1437.
15. Nivoit P, Wiernsperger N, Moulin P, Lagarde M, Renaudin C. Effect of glycated LDL on microvascular tone in mice: a comparative study with LDL modified in vitro or isolated from diabetic patients. Diabetologia 2003. 46:1550-1558.
16. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002. 25:1439-1443.
17. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR. Postprandial low density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 1999. 222:178-184.
18. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C. Meal induced oxidative stress and low-density lipoprotein (LDL) oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999. 48:1503-1508.
19. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radical Biol Med 2000. 28:1815-1826.
20. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular survey methods. 2nd edition. World Health Organization 1982, anex 1.
21. Howard BV, Lee ET, Cowan L, Fabsitz R, Oopik AJ, Robbins DC, Savage PJ, Yeh JL, Welty TK. Coronary heart disease prevalence and its relation to heart disease in American Indians: The Strong Heart Study. Am J Epidemiol 1995. 142:254-268.
22. Friedwald WT, Levy R, Fredrickson DS. Estimations of serum low density lipoprotein cholesterol without use of preparative ultracentrifuge. Clin Chem 1972. 18:499-502.
23. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999. 16:716-730.
24. Chung BH, Wilkinson T, Geer JC, Segrest JP. Preparative and quantitative isolation of plasma lipoproteins: rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 1980. 21:284-291.
25. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995. 96:2322-2330.
26. Kim BS, LaBella FS. Comparison of analytical methods for monitoring autoxidation profiles of authentic lipids. J Lipid Res 1987. 28:1110-1117.
27. Esterbauer H, Gebicki J, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biol Med 1992. 13:341-390.
28. Krolewski AS, Warram JH, Valsania P, Martin BC, Laffel LMB, Christlieb AR. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991. 90:S56-S61.
29. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997. 272:20963-20966.
30. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radical Biol Med 1996. 20:707-727.
31. Marathe GK, Davies SS, Harrison KA, Silva AR, Murphy RC, Castro-Faria-Neto H, Prescott SM, Zimmerman GA, McIntyre TM. Inflammatory platelet-activating factor-like phospholipids in oxidized low density lipoproteins are fragmented alkyl phosphatidylcholines. J Biol Chem 1999. 274:28395-28404.
32. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996. 347:781-786.
33. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardical infarction: results of the GISSI-Prevenzione trial. Lancet 1999. 354:447-455.
34. Leppala JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 2000. 20:230-235.
35. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N Engl J Med 2000. 342:154-160.
36. Brockes C, Buchili C, Locher R, Koch J, Velter W. Vitamin E prevents extensive lipid peroxidation in patients with hypertension. Br J Biomed Sci 2003. 60:5-8.
37. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994. 43:1010-1014.
38. Liguori A, Abete P, Hayden JM, Cacciatore F, Rengo F, Ambrosio G, Bonaduce D, Condorelli M, Reaven PD, Napoli C. Effect of glycaemic control and age on low-density lipoprotein susceptibility to oxidation in diabetes mellitus type 1. Eur Heart J 2001. 22:2075-2084.
39. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 1996. 45:762-767.
40. Kuyvenhoven JP, Meinders AE. Oxidative stress and diabetes mellitus – Pathogenesis of long-term complications. Eur J Intern Med 1999. 10:9-19.
41. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996. 39:1577-1583.
42. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T. Diabetes and cardiovascular disease in a prospective population survey in Japan: The Hisayama Study. Diabetes 1996. 45:S14-S16.
43. Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocrinol J 1995. 42:461-465.
44. Nhadimana J, Dorchy H, Vertongen F. Activité anti-oxydante erythrocytaire et plasmatique dans le diabète de type I. Presse Méd 1996. 25:188-192.
45. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Riggs JE, Warehime SS, Christie I, Ganser G, Van Dyke K. Nitrosative stress, uric acid and peripheral nerve function in early type 1 diabetes. Diabetes 2002. 51:2817-2825.
46. Heyden S, Heiss G, Bartel AG, Hames CG. Sex differences in coronary mortality among diabetics in Evans County, Georgia. J Chron Dis 1980. 33:265-273.
47. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999. 281:1291-1297.
48. Dabelea D, Kinney G, Snell-Bergeon JK, Hokanson JE, Eckel RH, Ehrlich J, Garg S, Hamman RF, Rewers M; The Coronary Artery Calcification in Type 1 Diabetes Study. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? The Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. Diabetes 2003. 52:2833-2839.
49. Colhoum HM, Rubens MB, Underwood R, Fuller JH. The effect of type 1 diabetes mellitus on the gender difference in coronary artery calcification. J Am Coll Cardiol 2000. 36:2160-2167.
50. Colhoum HM, Otvos JD, Rubens MB, Taskinen MR, Underwood SR, Fuller JH. Lipoprotein subclasses and particle size and their relation with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes 2002. 51:1949-1956.
51. Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo MA, Ruotolo V, Caputo S, Giardina B, Ghirlanda G, Santini SA. Early increase of oxidative stress and reduced antioxidant defenses in patients with uncomplicated type 1 diabetes. Diabetes Care 2002. 25:370-375.
52. Steinberg HO, Paradisi G, Cronin J, Crowde K, Hempfling A, Hook G, Baron AD. Type II diabetes abrogates gender differences in endothelial function in premenopausal women. Circulation 2000. 101:2040-2046.
53. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992. 117:1016-1037.
54. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17 beta-estradiol attenuates acetylcholine-induced coronary artery disease. Circulation 1995. 92:24-30.
55. Willems D, Dorchy H, Dufrasne D. Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atherosclerosis 1998. 137:S61-S64.